This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Newmont Corporation (NEM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NEMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
by Zacks Equity Research
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
GSKNegative Net Change DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
BIIBNegative Net Change IRWDNegative Net Change BMYNegative Net Change VERVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMYNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs cancer cell-therapy medical pharmaceuticals
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
by Zacks Equity Research
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change MURANo Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
by Zacks Equity Research
Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change DTILNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
by Zacks Equity Research
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
LLYNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change VERVNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
by Ahan Chakraborty
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
PFEPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
by Zacks Equity Research
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
BMYNegative Net Change FOLDNegative Net Change CYTKPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
by Zacks Equity Research
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
BAYRYPositive Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
by Zacks Equity Research
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
NVSPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology medical pharmaceuticals
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
by Zacks Equity Research
The stock rallies 18.5% after Keros initiates a strategic review process exploring alternatives, including a potential sale of the business.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
by Zacks Equity Research
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change PHIONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
by Zacks Equity Research
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
by Ekta Bagri
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
AZNPositive Net Change NVONegative Net Change LLYNegative Net Change ABBVPositive Net Change
biotechnology medical pharmaceuticals
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
BMYNegative Net Change AMGNNegative Net Change SRPTNegative Net Change PCRXNegative Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change RXRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
DVAXNegative Net Change BAYRYPositive Net Change PCRXNegative Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
DVAXNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change RYTMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
PFEPositive Net Change BMRNNegative Net Change ADMAPositive Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
GILDPositive Net Change BMRNNegative Net Change FOLDNegative Net Change ADMAPositive Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
BAYRYPositive Net Change CYTKPositive Net Change ADMAPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
by Zacks Equity Research
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
BIAFNegative Net Change
biotechnology biotechs earnings medical
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
by Supriyo Bose
ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.
GLWNegative Net Change JAZZPositive Net Change PPCPositive Net Change ANETNegative Net Change
biotechnology cloud-computing communications consumer-discretionary energy